Pharmacists in Villas, NJ Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Kristine Rodrigues Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-1166 |
Dr. Sandra Ude, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-1166 |
Kelsy Lucas Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-1166 Fax: 609-886-1255 |
Aubrianna Borger, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 Bayshore Rd, Villas, NJ 08251 Phone: 609-886-1166 |
News Archive
Specific mutations in FLT3 receptor can contribute to acute myeloid leukemia
Specific mutations (N676K) in the FLT3 receptor can contribute to the development of acute myeloid leukemia. The FLT3 receptor regulates cell growth, while activating gene mutations promote the uncontrolled proliferation of white blood cells. These findings were reported in the specialist journal Blood by a group of scientists from the Helmholtz Zentrum München and the Hospital of the Ludwig Maximilians University in Munich as part of a clinical research collaboration with the German Cancer Consortium.
Study finds high levels of cancer-fighting TRAIL in human milk
The benefits of breast milk are well known, but why breastfeeding protects against various forms of cancer remains a mystery. A new study in the Journal of Human Lactation found high levels of cancer-fighting TNF-related apoptosis inducing ligand (TRAIL) in human milk, which might be one source of breast milk's anticancer activity.
Children at increased risk for heat-related illness
Extreme heat continues to plague the nation with many areas seeing record temperatures. Though everyone needs to take precautions when it comes to dangerous heat, it's especially important to watch your kids. Children are at a greater risk than adults of sustaining a heat injury.
Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development
SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.
› Verified 4 days ago